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of patients treated with linezolid versus vancomycin were cured
(69.6% versus 55.4%). Average total treatment cost was
$14,268 for linezolid-treated patients versus $13,065 for van-
comycin-treated patients, with an incremental ratio of $8429 per
additional patient cured. Death rates were 20.4% for linezolid
versus 35% for vancomycin, with an average 2.49 life-years
gained per linezolid patient in a 65-year-old cohort (13.7 versus
11.2 years). The incremental cost per death avoided and per life
year gained were $7299 and $482, respectively. To evaluate the
robustness of ﬁndings sensitivity analyses were carried out mod-
ifying the value of several key variables. As a result of changing
them suitably, the overall conclusions remained the same. CON-
CLUSION: From the Argentinean perspective, linezolid is cost-
effective versus vancomycin in the treatment of nosocomial
pneumonia due to suspected MRSA.
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OBJECTIVES: Ventilator—associated pneumonia (VAP)
remains a signiﬁcant cause of morbidity and mortality in
Mexico. Development of VAP increases both the duration of
intensive care unit (ICU) stay and hospitalization. The purpose
of this study was to compare the cost—effectiveness ratios
between four antimicrobial treatments for hospitalized adult
patients with suspected or proven Gram-positive VAP due to
Staphylococcus aureus in two ICUs of the Social Security
Mexican Institute. METHODS: A decision tree model was devel-
oped using a Bayesian approach. The model simulated treatment
of a hypothetical cohort of 1000 patients diagnosed with VAP
during a time horizon of 12 weeks. Patients initiate treatment
with one of four antimicrobial agents; linezolid, vancomycin,
teicoplanin and imipenem. Conditional probabilities of the
model were obtained from published clinical trials. Effectiveness
measure was the clinical cure rate for patients with suspected or
proven Staphylococcus aureus VAP. The analysis was conducted
from the healthcare payer’s perspective (only direct medical costs
were used). Resource use and costs were obtained from hospital
records and Mexican ofﬁcial databases. Probabilistic sensitivity
analysis was performed and acceptability and health net beneﬁts
curves were constructed. RESULTS: Linezolid was associated
with a shorter ICU stay and a higher clinical cure in comparison
with vancomicyn, teicoplanin and imipenem (p < 0.005). Line-
zolid showed on the 12-weeks period the lowest expected
average costs per patient treated (US$38,182.9) followed by van-
comicyn (US$39,345.5) and imipenem (US$42,235). Linezolid
also showed the highest clinical cure rate (57.4%) followed by
vancomcyin (37.2%) and teicoplanin (32.1%). Results were
robust to Monte Carlo ﬁrst order sensitivity analysis. CON-
CLUSIONS: Despite its higher cost in the Mexican market, line-
zolid was cost—effective for treatment of VAP. These results
should be taken into account by Mexican decision makers and
clinicians in the management of patients with suspected or
proven Gram-positive VAP due to Staphylococcus aureus.
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OBJECTIVES: The non-peptidic protease inhibitor (PI)
tipranavir boosted with ritonavir (TPV/r) has shown superior
efﬁcacy compared to investigator selected ritonavir-boosted com-
parator PI (CPI/r) in treatment experienced HIV 1 infected
patients in the RESIST 1 and 2 clinical trials. TPV/r or CPI/r were
administered with an optimized background regimen (OBR). In
addition to the clinical efﬁcacy of TPV/r, healthcare decision-
makers will be interested in the cost-effectiveness of TPV/r.
METHODS: A previously published 3-stage Markov model 
was modiﬁed to reﬂect US practice patterns for treatment-
experienced HIV patients using 2005 costs and combined 48-
week RESIST 1 and 2 trial data. The 12 model health states (HS)
were deﬁned by patients’ CD4+ count and viral load, with cost
and risk of AIDS deﬁning events (ADEs) being linked to each
HS. Cycle length was three months and transition through the
model continued until 90% of patients had died. Disease pro-
gression beyond the 48-week trial data was based on HAART
treatment experienced patients from the Medical University of
South Carolina database. Costs were estimated from the payer
perspective, including AWP drug prices and costs for patient
monitoring and ADEs from SC Medicaid patients. RESULTS:
TPV/r patients remained longer in HS deﬁned by higher CD4+
count and lower viral load compared to CPI/r patients. This
reduced the rate of ADEs (12.35% over 5 years) and resulted in
9.6 quality-adjusted life-months gained over the model time
horizon. The incremental cost-effectiveness ratio (ICER) of
TPV/r vs. CPI/r was $56,668 per QALY (discounted at 3%). Sub-
group analysis of patients not treated with enfuvirtide as part of
their OBR reduced the ICER to $49,467 per QALY. CONCLU-
SIONS: The ICER for TPV/r falls well within the $/QALY range
of $50,000–$100,000 considered acceptable. Treating patients
with TPV/r in earlier treatment regimes, not requiring augmen-
tation with enfuvirtide, yielded an ICER below $50,000 per
QALY.
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OBJECTIVES: Nosocomial pneumonia (NP) is costly in terms
of resource utilization and mortality. Patients with ventilator-
associated pneumonia (VAP) have a higher risk of death than
those with NP from other sources. The differences in risk and
costs are attributable in part, to differences in the underlying
pathogens. The purpose of this study is to characterize the out-
comes and costs associated with NP, speciﬁcally examining 
the impact of mechanical ventilation. METHODS: We used
Premier’s 2003 hospital dataset for this study. These data origi-
nate from 1500 hospitals in the United States. Records with a
non-missing admission code and a diagnosis of pneumonia some-
time during the stay were retained. To restrict the sample to those
with NP, records with a diagnosis of pneumonia at admission as
well as those with an antibiotic on day one were deleted. CPT-
codes were used to identify mechanical ventilation and text
strings were searched to identify antibiotic therapy. Length of
stay and costs were calculated by ward type. RESULTS: The ﬁnal
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analytical sample contained 26,349 admissions: 762 stays
involved mechanical ventilation, 9495 had ICU time, and 16,092
had neither. Hospital mortality rates were 27.7%, 23.8% and
7.6% for these three groups, respectively. Median cost per stay
was substantially higher for those with ventilation ($39,493)
versus those with ICU time but no ventilation ($25,798) and
those with neither ($7261). Average length of stay in the ICU
was 14 days and 9 days for those with and without ventilation,
respectively. Average anti-infective drug costs were 1.79 times
higher in the ventilator group compared with the ICU group.
CONCLUSION: VAP is an area of high unmet need. Among
these 1500 hospitals, 2003 costs for those with mechanical ven-
tilation were 1.5 times higher than a group of NP cases that were
fairly complex, as indicated by some receipt of intensive care 
services.
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OBJECTIVE: To estimate lifetime medical cost of chronic hepati-
tis B in the United States from the societal perspective.
METHODS: A hypothetical 35-year old cohort of 100,000 indi-
viduals with chronic hepatitis B was tracked in a Markov model
of the natural history of disease. The model assumed standard
clinical care for disease complications, but did not include antivi-
ral treatment. Disease outcomes modeled included cirrhosis,
hepatocellular carcinoma, liver transplantation and death.
Annual transition parameters were estimated from long-term
disease progression data in the literature. Outcome speciﬁc cost
data were derived from published studies and the MarketScan®
database. Expected lifetime medical cost was determined as the
sum of weighted average medical cost of health outcomes over
the cohort lifetime discounted at 3% annual rate and adjusted
to 2005 U.S. dollars. Impact of variations in model parameters
was assessed in one-way sensitivity analyses. RESULTS: The
expected per patient lifetime medical cost of chronic hepatitis B
for the 35-year old cohort was $34,760 (range in sensitivity
analyses: $9367−$59,298). About 73% of the cost was for cir-
rhosis, 10% for hepatocellular carcinoma and 11% for liver
transplantation. The cost varied with the initial age at infection
of the cohort: for a cohort aged 25 years at infection, the cost
was 11% more than the cost for the 35-year olds, and for a 
45-year old cohort, the cost was 16% less than the cost for the
35-year olds. The cost estimate was most sensitive to the annual
rate of developing compensated cirrhosis. CONCLUSIONS:
Life-time medical cost of a chronic hepatitis B patient is sub-
stantial. Identiﬁcation of the disease at early stage for anti-
viral treatment could reduce the likelihood of developing end-
stage liver diseases and avert higher costs.
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OBJECTIVE: To evaluate the economic implications of upper
respiratory tract infection to the Nigerian society. METHODS:
It involves Cost of Illness analysis among upper respiratory tract
infection Out- Patients in Lagos University Teaching Hospital.
Data collected from 182 case notes include; demographics, diag-
nosis, diagnostic tests, no of visits, and prescribed drugs. Direct
and indirect costs were included. The costs include, personnel,
diagnostic tests, transport and antibacterial cost. The hospital
cost of drugs and tests were used. Stop-watch time studies and
monthly earnings were used to calculate the personnel costs.
Average time spent at each visit and expected earnings were used
to calculate the indirect costs. The current hospital costs were
used for all calculations hence neither discounting nor inﬂation
was considered. RESULTS: Total cost of drugs = N358,790.00
($2462.80); Average = N1971.40 ($14.10) Personnel cost =
N49,156.40 ($351.12); Average = N270.00 ($1.93) Diagnostic
Test cost = N9100.00 ($65.00); Average = N50.00 ($0.36) Trans-
port cost = N36,930.00 ($263.80); Average = N202.91 ($1.45)
Indirect cost = N103,350.00 ($738.21) Average = N567.86
($4.06) Cost of illness = N557,326.40 ($3981.10) Average =
N3062.23 ($21.87). Cost of drugs for each disease condition
Acute Otitis media (n = 45 = N24, 526.00 ($175.20); Average =
N545.02 ($3.90). Chronic Superative Otitis media (n = 37) = N
42,982.00 ($307.01); Average = N1161.68 ($8.30) onchopneu-
monia (n = 70) = N257, 299.00 ($1837.85); Average = N
3675.41 ($26.25) Tonsilitis (n = 12) = N14, 923.00 ($106.60);
Average = N1243.58 ($8.90). Other) = N19060.00 ($136.14);
Average = N1058.94 ($7.56). Prevalence of Otitis media in
Nigeria = 29.0% in children below 5 years. = 7,772,000 cases
(7.7million cases) Average cost of Otitis media = N823.27
($5.88) Cost of drugs for 7.7 million cases of otitis media alone
= N6, 398,454,440.00 (Over N6.3 billion) (>$450million).
CONCLUSION: Cost of therapy associated with URTI is enor-
mous. This high cost might be partly due to the use of antibi-
otics in most cases of URTI, a good proportion of which are
viral. The use of treatment guidelines is necessary to ensure a
wise use of the limited resources.
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OBJECTIVES: To estimate direct medical costs associated to
adult patients with HIV/AIDS in second and third level hospitals
in the Social Security Mexican Institute. METHODS: Partial eco-
nomic evaluation was performed employing a one-year survey to
identify patients with HIV/AIDS resource use. The study revised
hospital records in 8 second level hospitals and 2 third level hos-
pitals in Mexico City throughout 2003. Resource use estimates
include outpatient and inpatients services (visits to physicians or
specialists, laboratory and gabinet exams, medications, emer-
gency services, hospitalization, etc.). The research estimates total
direct medical costs and average costs per patient per year. The
analysis was conducted from the healthcare payer’s perspective.
All costs were expressed in 2005 US$. RESULTS: A total of 1969
adult patients with HIV/AIDS were recruited with an average age
of 39 ± 10 years; 86.4% were male. The evolution average time
with HIV was of 6 ± 3 years. 29% of patients were in clinical
stage A; 26% in clinical stage B and 45% in clinical stage C. The
total direct medical cost of these patients on a 1-year follow up
was US$1.107.952,58. Eighty-eight percent of this amount cor-
responds to antiretroviral drugs, 10% to physician’s or special-
ists visits and 2% to non-antiretroviral drugs and laboratory
exams. A total of 9.6% of the sample required inpatient services
with a mean cost per patient of US$ 3103.2. Outpatient services
had an annual mean cost per patient of US$ 5665.1 and the
annual expected cost per patient in the Social Security Mexican
Institute was estimated in US$ 5964.6. CONCLUSIONS: Eco-
nomic consequences of HIV/AIDS patients are substantial for the
Mexican Health Budget, especially due to antiretroviral drugs.
